PCSK6 and prostate carcinoma: In prostate cancer cells (Figure 3(a)), PACE4-knockdown diminished 64Cu/NOTA-ML uptake by 40% in both LNCaP (8 versus 13%/106 cells after 2 h) and DU145 cells (1.8 versus 3.6%/106 cells after 2 h).